LIFECORE BIOMEDICAL INC (LFCR) Stock Price, Quote, News and Overview
NASDAQ:LFCR - Nasdaq - US5147661046 - Common Stock - Currency: USD
LFCR Quote, Performance and Key Statistics
6.18
+0.03 (+0.49%)
The current stock price of LFCR is 6.18 USD. In the past month the price increased by 0.82%. In the past year, price decreased by -22.07%.
LFCR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.32 | 200.59B | ||
| DHR | DANAHER CORP | 28.31 | 151.57B | ||
| A | AGILENT TECHNOLOGIES INC | 23.86 | 36.12B | ||
| IQV | IQVIA HOLDINGS INC | 17.2 | 33.79B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.38 | 27.02B | ||
| WAT | WATERS CORP | 33.11 | 23.35B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 34.29 | 16.74B | ||
| ICLR | ICON PLC | 13.33 | 15.40B | ||
| RVTY | REVVITY INC | 23.99 | 14.13B | ||
| ILMN | ILLUMINA INC | 35.36 | 13.72B | ||
| AVTR | AVANTOR INC | 17.5 | 11.92B | ||
| TECH | BIO-TECHNE CORP | 35.56 | 10.18B |
Related stock screener links
About LFCR
Company Profile
Lifecore Biomedical, Inc. is a contract development and manufacturing organization, which engages in the provision of differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is headquartered in Chaska, Minnesota and currently employs 524 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Company Info
LIFECORE BIOMEDICAL INC
3515 Lyman Boulevard
Chaska MINNESOTA US
Employees: 524
Company Website: https://www.lifecore.com/
Investor Relations: https://ir.lifecore.com/
Phone: 19523684300
LIFECORE BIOMEDICAL INC / LFCR FAQ
What is the stock price of LIFECORE BIOMEDICAL INC today?
The current stock price of LFCR is 6.18 USD. The price increased by 0.49% in the last trading session.
What is the ticker symbol for LIFECORE BIOMEDICAL INC stock?
The exchange symbol of LIFECORE BIOMEDICAL INC is LFCR and it is listed on the Nasdaq exchange.
On which exchange is LFCR stock listed?
LFCR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LIFECORE BIOMEDICAL INC stock?
9 analysts have analysed LFCR and the average price target is 8.67 USD. This implies a price increase of 40.29% is expected in the next year compared to the current price of 6.18. Check the LIFECORE BIOMEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LIFECORE BIOMEDICAL INC worth?
LIFECORE BIOMEDICAL INC (LFCR) has a market capitalization of 228.85M USD. This makes LFCR a Micro Cap stock.
How many employees does LIFECORE BIOMEDICAL INC have?
LIFECORE BIOMEDICAL INC (LFCR) currently has 524 employees.
What are the support and resistance levels for LIFECORE BIOMEDICAL INC (LFCR) stock?
LIFECORE BIOMEDICAL INC (LFCR) has a support level at 5.73 and a resistance level at 6.19. Check the full technical report for a detailed analysis of LFCR support and resistance levels.
Is LIFECORE BIOMEDICAL INC (LFCR) expected to grow?
The Revenue of LIFECORE BIOMEDICAL INC (LFCR) is expected to grow by 2.52% in the next year. Check the estimates tab for more information on the LFCR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LIFECORE BIOMEDICAL INC (LFCR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LFCR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LFCR, evaluating the profitability, health, valuation and growth aspects
- LIFECORE BIOMEDICAL INC (LFCR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LIFECORE BIOMEDICAL INC (LFCR) Sales and EPS estimates to see what analysts future expectations are.
- LIFECORE BIOMEDICAL INC (LFCR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LIFECORE BIOMEDICAL INC (LFCR) Insider and Institutional Ownership to learn about the owners and their transactions.
- LIFECORE BIOMEDICAL INC (LFCR) Stock Chart to make your own analysis
- LIFECORE BIOMEDICAL INC (LFCR) Latest news and press-releases to stay up to date.
Does LIFECORE BIOMEDICAL INC (LFCR) stock pay dividends?
LFCR does not pay a dividend.
When does LIFECORE BIOMEDICAL INC (LFCR) report earnings?
LIFECORE BIOMEDICAL INC (LFCR) will report earnings on 2025-04-02, before the market open.
What is the Price/Earnings (PE) ratio of LIFECORE BIOMEDICAL INC (LFCR)?
LIFECORE BIOMEDICAL INC (LFCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.59).
What is the Short Interest ratio of LIFECORE BIOMEDICAL INC (LFCR) stock?
The outstanding short interest for LIFECORE BIOMEDICAL INC (LFCR) is 6.85% of its float. Check the ownership tab for more information on the LFCR short interest.
LFCR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to LFCR. When comparing the yearly performance of all stocks, LFCR is a bad performer in the overall market: 79.6% of all stocks are doing better.
LFCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LFCR. LFCR may be in some trouble as it scores bad on both profitability and health.
LFCR Financial Highlights
Over the last trailing twelve months LFCR reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS increased by 75.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.42% | ||
| ROE | -27.42% | ||
| Debt/Equity | 1.99 |
LFCR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to LFCR. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -304.88% and a revenue growth 2.52% for LFCR